
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is well-positioned due to their large market share in the Americas, recent focus on digital health, and strong financial performance with a solid gross margin of 62.3%. Despite a downwards trend in projected revenue growth in the next few years, the company's acquisition of MatrixCare for $490m highlights its commitment to growth through strategic acquisitions. ResMed's efforts to integrate sustainability into its strategy, from product safety to environmental initiatives, also showcase the company's long-term vision and commitment to responsible business practices.
Bears say
ResMed is suffering from potential disruptions in the sleep apnea market as GLP-1 drugs and expanded indications may reduce PAP volumes, despite their projection of continued growth in devices, masks, and SaaS revenue. Additionally, their gross margin of 61% and expansive global market may not be enough to offset this potential disruption, leading to a Hold rating.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares